rejuvant life tabs

114 year-old cells converted to pluripotent stem cells

Latest articles

Paving the way to future organ factories

Extracellular matrix obtained by controlled decellularisation is used to reconstruct the liver with human-like characteristics, paving the way for transplantable livers. Researchers at the Human...

Charles Brenner: the journey from NR to Tru Niagen

Dr Charles Brenner, the developer of the intellectual property behind ChromaDex's Tru Niagen, on all things metabolism, NAD and NR clinical trials. Longevity.Technology: Following the...

Longevity investment firm announces acceleration programme

Call for future founders: longevity investment fund LongeVC announces in-house acceleration programme. LongeVC – a longevity investment group backed by an advisory board with solid...

The placenta: a limitless source of stem cells?

Part 1 of our exclusive interview with Celularity founder Dr Robert Hariri covers the discovery of placental pluripotent stem cells and the journey towards...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Paving the way to future organ factories

Extracellular matrix obtained by controlled decellularisation is used to reconstruct the liver with human-like characteristics, paving the way for transplantable livers. Researchers at the Human...

Charles Brenner: the journey from NR to Tru Niagen

Dr Charles Brenner, the developer of the intellectual property behind ChromaDex's Tru Niagen, on all things metabolism, NAD and NR clinical trials. Longevity.Technology: Following the...

Longevity investment firm announces acceleration programme

Call for future founders: longevity investment fund LongeVC announces in-house acceleration programme. LongeVC – a longevity investment group backed by an advisory board with solid...
Rejuvant

AgeX publishes evidence of supercentenarian cellular age reversal: new paper supports hypothesis of no upper age limit for reprogramming cellular aging. This is big news for Longevity research.

Supercentenarians, defined as people who have reached the age of 110, have long-confounded the scientific community due to the fact that they also typically live a life free of major age-related diseases until shortly before their death. New research [1] published today could lead to new insights into the fundamental mechanisms of aging and why supercentenarians not only live the longest, but also why they experience such extraordinary healthspans.


“We can essentially put their cells in a time machine and revert them to an earlier state …”


 

Longevity focused biotech firm AgeX Therapeutics (NYSE American: AGE), today announced the publication of a new paper in the peer-reviewed scientific journal “Biochemical and Biophysical Research Communications.”

The paper documents the work conducted by AgeX scientists, among others, who converted the cells of a deceased 114-year-old into young pluripotent stem cells, demonstrating first-time evidence of reversal of the telomere aging clock in a supercentenarian’s cells. The research introduces the possibility of identifying the underlying biology of extreme human lifespan and healthspan.

The donated cells were from “the longevity collection” a cell bank established by NIH’s National Institute on Aging.

“Clearly, we can learn a lot about aging and longevity from the longest of the long-lived, the supercentenarians, and we hope that this paper accelerates such research,” said the paper’s senior author, Dana Larocca, PhD, VP of Discovery Research at AgeX. “Now that we have converted the cells of one of the longest-lived people in history, a deceased 114-year-old American woman, to a young pluripotent state, researchers can do so with cells from other supercentenarians.”

Elevant

“The goal is to understand specifically how these “extreme agers” manage to avoid the major chronic illnesses of aging better than any other age group including centenarians,” added Dr. Larocca. “We can essentially put their cells in a time machine and revert them to an earlier state, then study their biology to help unlock the mysteries of super-longevity. Scientists have long wondered, and now we know that we can indeed reset the developmental state and cellular age in the ‘oldest of the old.’”

Longevity Technology HEalthspan Lifespan
Healthspan and morbidity explainer: Super-centenarians have no major diseases through their longer life and experience compressed morbidity

Elevant

By way of comparison the paper also describes undertaking a similar process with cells from two other donors: an eight-year-old with a rapid-aging syndrome commonly known as Progeria, and a 43-year-old, healthy disease-free control (HDC) subject. The paper notes that the supercentenarian’s cells reverted to induced pluripotent stem (iPS) cells at the same rate as the HDC subject and the Progeria patient. However, there may be some negative impact of extreme age on telomere resetting as this did not occur as frequently in the supercentenarian as in the other two donors.

This is very exciting news for research in the field of rejuvenation therapies and comes close behind other news from AgeX: the research collaboration with the University of California, Irvine using AgeX’s PureStem technology to derive neural stem cells; and a research collaboration with an as-yet-undisclosed Japanese biopharm company to further the development of its immunotolerance technology platform.

[1] https://www.sciencedirect.com/science/article/pii/S0006291X20303661?via%3Dihub
Image by analogicus from Pixabay 
Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of First Longevity which brings together international investors and Longevity start-ups.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Paving the way to future organ factories

Extracellular matrix obtained by controlled decellularisation is used to reconstruct the liver with human-like characteristics, paving the way for transplantable livers. Researchers at the Human...

The placenta: a limitless source of stem cells?

Part 1 of our exclusive interview with Celularity founder Dr Robert Hariri covers the discovery of placental pluripotent stem cells and the journey towards...

Insulin – predictor of longevity

Body weight stands for far more than simple aesthetics – it is key for longevity. From a single cell to a fully functioning human adult,...

Juvenescence debuts ketosis longevity supplement drink

Biotech Juvenescence's new product Metabolic Switch is a drink that supports healthy aging and a healthy metabolism by generating a state of ketosis. It's been...

Targeting neurodegeneration with $82m Series A

Alchemab raises £60 million to advance novel platform for identifying disease-modifying antibody therapeutics for neurodegeneration, cancer and more. UK-based biotech Alchemab Therapeutics has secured a...
Supps report ad middle